Shopping Cart 0
Cart Subtotal
USD 0

Age Related Macular Degeneration-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Age Related Macular Degeneration-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration-Pipeline Review, H2 2017, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 27, 18, 4, 135, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 16 and 2 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Age Related Macular Degeneration-Overview

Age Related Macular Degeneration-Therapeutics Development

Age Related Macular Degeneration-Therapeutics Assessment

Age Related Macular Degeneration-Companies Involved in Therapeutics Development

Age Related Macular Degeneration-Drug Profiles

Age Related Macular Degeneration-Dormant Projects

Age Related Macular Degeneration-Discontinued Products

Age Related Macular Degeneration-Product Development Milestones 50

Appendix


List Of Figure

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Age Related Macular Degeneration-Pipeline by 3SBio Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Abzena Plc, H2 2017

Age Related Macular Degeneration-Pipeline by Achillion Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Aciont Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Acucela Inc, H2 2017

Age Related Macular Degeneration-Pipeline by AdAlta Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Adverum Biotechnologies Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Aerie Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Aerpio Therapeutics Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Alimera Sciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Alkeus Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Allergan Plc, H2 2017

Age Related Macular Degeneration-Pipeline by Allgenesis Biotherapeutics Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Allinky Biopharma, H2 2017

Age Related Macular Degeneration-Pipeline by Alteogen Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Amarna Therapeutics BV, H2 2017

Age Related Macular Degeneration-Pipeline by Apellis Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Apexigen Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Applied Genetic Technologies Corp, H2 2017

Age Related Macular Degeneration-Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Astellas Pharma Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Benitec Biopharma Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Biokine Therapeutics Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by BioMAS Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Biomics Biotechnologies Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Biophytis SAS, H2 2017

Age Related Macular Degeneration-Pipeline by Caladrius Biosciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Catalyst Biosciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Cell Cure Neurosciences Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Cell Medica Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Charlesson LLC, H2 2017

Age Related Macular Degeneration-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Age Related Macular Degeneration-Pipeline by CJ HealthCare Corp, H2 2017

Age Related Macular Degeneration-Pipeline by Clanotech AB, H2 2017

Age Related Macular Degeneration-Pipeline by Coherus BioSciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Colby Pharmaceutical Co, H2 2017

Age Related Macular Degeneration-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Diffusion Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Eleven Biotherapeutics Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Elsalys Biotech SAS, H2 2017

Age Related Macular Degeneration-Pipeline by Enzene Biosciences Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Exonate Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by EyeGate Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Eyevensys SAS, H2 2017

Age Related Macular Degeneration-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by FirstString Research Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Foamix Pharmaceuticals Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Formycon AG, H2 2017

Age Related Macular Degeneration-Pipeline by Gene Techno Science Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Genentech Inc, H2 2017

Age Related Macular Degeneration-Pipeline by GenSight Biologics SA, H2 2017

Age Related Macular Degeneration-Pipeline by Graybug Vision Inc, H2 2017

Age Related Macular Degeneration-Pipeline by HanAll Biopharma Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Huabo Biopharm Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Icon Bioscience Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Iconic Therapeutics Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Inception Sciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Innovent Biologics Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Intellect Neurosciences Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Age Related Macular Degeneration-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Age Related Macular Degeneration-Pipeline by Johnson & Johnson, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

3SBio Inc

Abzena Plc

Achillion Pharmaceuticals Inc

Aciont Inc

Acucela Inc

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aerpio Therapeutics Inc

Alimera Sciences Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma

Alteogen Inc

Amarna Therapeutics BV

Apellis Pharmaceuticals Inc

Apexigen Inc

Applied Genetic Technologies Corp

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Benitec Biopharma Ltd

Biokine Therapeutics Ltd

BioMAS Ltd

Biomics Biotechnologies Co Ltd

Biophytis SAS

Caladrius Biosciences Inc

Catalyst Biosciences Inc

Cell Cure Neurosciences Ltd

Cell Medica Ltd

Charlesson LLC

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Clanotech AB

Coherus BioSciences Inc

Colby Pharmaceutical Co

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Diffusion Pharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

Eleven Biotherapeutics Inc

Elsalys Biotech SAS

Enzene Biosciences Ltd

Exonate Ltd

EyeGate Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Foamix Pharmaceuticals Ltd

Formycon AG

Gene Techno Science Co Ltd

Genentech Inc

GenSight Biologics SA

Graybug Vision Inc

HanAll Biopharma Co Ltd

Huabo Biopharm Co Ltd

Icon Bioscience Inc

Iconic Therapeutics Inc

Ildong Pharmaceutical Co Ltd

Inception Sciences Inc

Innovent Biologics Inc

Intellect Neurosciences Inc

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Just Biotherapeutics Inc

Kala Pharmaceuticals Inc

Kodiak Sciences Inc

Lead Discovery Center GmbH

LeadArtis SL

Lee's Pharmaceutical Holdings Ltd

Lupin Ltd

M's Science Corp

Mabion SA

MacuCLEAR Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mor Research Application Ltd

Navya Biologicals Pvt Ltd

Neovacs SA

Novartis AG

NovelMed Therapeutics Inc

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Ophthotech Corp

Oxford BioMedica Plc

Oxular Ltd

PanOptica Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

Pfizer Inc

PlantForm Corp

Promedior Inc

pSivida Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Ribomic Inc

RXi Pharmaceuticals Corp

SanBio Inc

SciFluor Life Sciences LLC

Senju Pharmaceutical Co Ltd

Stealth BioTherapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

TRACON Pharmaceuticals Inc

Tyrogenex Inc

Wellstat Ophthalmics Corp

Xbrane Biopharma AB